iRhythm Technologies (NASDAQ:IRTC) Receives Consensus Rating of "Moderate Buy" from Brokerages

Key Points

• Shares of iRhythm carry a consensus rating of Moderate Buy from 15 analysts (11 buy, 2 strong buy, 1 hold, 1 sell) with an average 12‑month price target of $197.77.
• iRhythm's Q1 beat expectations with revenue of $199.4M (up 25.6% YoY) and EPS of -$0.35 versus consensus -$0.56, while FY2026 revenue guidance of ~$875–$885M was roughly in line with forecasts.
• Sentiment is mixed—several firms have cut price targets (e.g., Goldman to $147, Wells Fargo to $180) even as others raised theirs, and insiders have sold about 94,509 shares (~$12.7M) in the last 90 days, adding downward pressure on the stock.

Shares of iRhythm Technologies (NASDAQ:IRTC - Get Free Report) have earned a consensus rating of "Moderate Buy" from the fifteen ratings firms that are covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, eleven have issued a buy rating and two have issued a strong buy rating on the company. The average 12-month price target among brokerages that have issued ratings on the stock in the last year is $197.7692.

Several equities analysts have recently issued reports on the company. Wells Fargo & Company reduced their target price on iRhythm Technologies from $200.00 to $180.00 and set an "overweight" rating on the stock in a research note on Friday. Evercore raised iRhythm Technologies from an "in-line" rating to an "outperform" rating and boosted their target price for the company from $194.00 to $210.00 in a research note on Monday, January 5th. Canaccord Genuity Group reduced their target price on iRhythm Technologies from $198.00 to $180.00 and set a "buy" rating on the stock in a research note on Friday. The Goldman Sachs Group reduced their target price on iRhythm Technologies from $184.00 to $147.00 and set a "neutral" rating on the stock in a research note on Thursday, April 9th. Finally, Morgan Stanley reissued an "overweight" rating on shares of iRhythm Technologies in a research note on Monday, January 12th.

iRhythm Technologies Price Performance

Shares of iRhythm Technologies stock opened at $120.80 on Monday. The company has a debt-to-equity ratio of 4.03, a current ratio of 5.17 and a quick ratio of 4.98. The business's 50 day simple moving average is $122.93 and its two-hundred day simple moving average is $154.28. The stock has a market capitalization of $3.97 billion, a P/E ratio of -140.46 and a beta of 1.33. iRhythm Technologies has a one year low of $112.31 and a one year high of $212.00.

iRhythm Technologies (NASDAQ:IRTC - Get Free Report) last announced its quarterly earnings results on Thursday, April 30th. The company reported ($0.35) EPS for the quarter, topping analysts' consensus estimates of ($0.56) by $0.21. iRhythm Technologies had a negative return on equity of 10.26% and a negative net margin of 3.53%.The business had revenue of $199.39 million for the quarter, compared to analysts' expectations of $194.11 million. During the same period in the previous year, the firm earned ($0.97) EPS. The business's quarterly revenue was up 25.6% on a year-over-year basis. Analysts forecast that iRhythm Technologies will post -0.16 EPS for the current year.

Insider Activity

In other news, insider Chad Patterson sold 8,967 shares of the business's stock in a transaction that occurred on Wednesday, February 25th. The stock was sold at an average price of $135.42, for a total transaction of $1,214,311.14. Following the transaction, the insider directly owned 51,738 shares of the company's stock, valued at approximately $7,006,359.96. The trade was a 14.77% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Sumi Shrishrimal sold 6,217 shares of the business's stock in a transaction that occurred on Wednesday, February 25th. The shares were sold at an average price of $135.42, for a total value of $841,906.14. Following the transaction, the executive vice president directly owned 39,182 shares in the company, valued at $5,306,026.44. This trade represents a 13.69% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders sold 94,509 shares of company stock valued at $12,734,195. 0.98% of the stock is owned by insiders.

Institutional Investors Weigh In On iRhythm Technologies

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Measured Wealth Private Client Group LLC purchased a new stake in iRhythm Technologies in the third quarter worth $30,000. Root Financial Partners LLC purchased a new stake in iRhythm Technologies in the third quarter worth $30,000. GAMMA Investing LLC grew its stake in iRhythm Technologies by 48.4% in the fourth quarter. GAMMA Investing LLC now owns 184 shares of the company's stock worth $33,000 after purchasing an additional 60 shares during the period. Smartleaf Asset Management LLC grew its stake in iRhythm Technologies by 100.0% in the third quarter. Smartleaf Asset Management LLC now owns 198 shares of the company's stock worth $34,000 after purchasing an additional 99 shares during the period. Finally, FNY Investment Advisers LLC purchased a new stake in iRhythm Technologies in the third quarter worth $34,000.

iRhythm Technologies News Summary

Here are the key news stories impacting iRhythm Technologies this week:

• Positive Sentiment: Q1 results beat on revenue and EPS trends: iRhythm reported $199.4M in revenue (up 25.6% YoY) and a loss per share that was smaller than expected, indicating improving unit economics and topline momentum. This supports longer‑term growth expectations. IRTC Q1 results and call (MarketBeat)
• Positive Sentiment: Needham raised its price target slightly to $255 and keeps a "buy" rating, signaling conviction from at least one growth‑oriented shop and providing a bullish anchor for longer‑term upside. Needham raises PT to $255 (Benzinga)
• Neutral Sentiment: Company guidance: iRhythm issued FY2026 revenue guidance (~$875–$885M) roughly in line with consensus, which is steady but not clearly bullish; EPS guidance was not meaningfully changed. Guidance that meets expectations can temper upside momentum. IRTC Q1 financial results press release (GlobeNewswire)
• Neutral Sentiment: Additional context available from the Q1 earnings call transcript and analyst previews/deep dives — useful for investors evaluating margin progression, reimbursement/regulatory updates and AI initiatives but not immediate price catalysts by themselves. Q1 earnings call transcript (Seeking Alpha)
• Negative Sentiment: Analyst price‑target cuts from JPMorgan (PT lowered to $175 from $215) and Wells Fargo (PT lowered to $180 from $200) are exerting immediate downward pressure by reducing visible upside and prompting some investors to trim positions. JPMorgan & Wells Fargo lower PTs (Benzinga)
• Negative Sentiment: Truist and other outlets flagged cuts to targets in their Q1 previews, adding to the sell‑side pushback; persistent negative margins and a negative return on equity keep valuation sensitive to near‑term profitability improvements. Truist cuts PT on IRTC (Yahoo Finance)

About iRhythm Technologies

iRhythm Technologies, Inc is a medical technology company that develops and commercializes wearable cardiac monitoring devices and associated data analytics services. Founded in 2006 and headquartered in San Francisco, California, the company's flagship product is the Zio® patch, a discreet, single-use, continuous ECG recorder designed to monitor heart rhythms for up to 14 days. iRhythm's digital diagnostics platform combines biosensor technology with proprietary algorithms to detect arrhythmias and streamline data interpretation for physicians.

The Zio service is prescribed by cardiologists and other healthcare providers to aid in the diagnosis of atrial fibrillation, bradycardia, tachycardia and other rhythm disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.